Preclinical Development of Complement C5aR Antagonists for the Treatment of Motor Neuron Disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1118881

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

There is no cure for Motor Neuron Disease (MND) resulting in 2 Australian’s dying each day. Modification of the inflammation is one potential means of slowing MND. Our research team has identified a new series of potent anti-inflammatory compounds that may have potential to treat this disease. Our project will test these compounds in animal models of MND, and validate their usefulness in human MND samples. Ultimately, this work may contribute to the discovery of a new treatment for MND.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Development Grants

Funding Amount: $593,326.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Central Nervous System

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

complement C5a | drug development | efficacy | motor neuron disease (MND) | neuroinflammation

Related Links